Table 4 Descriptive statistics for plasma markers of inflammation and oxidative stress in randomized clinical trial 1
Marker | Baseline | Week 24 | p value |
|---|---|---|---|
CRP (mg/L) | |||
Control | 1.75 [0.00, 66.90] (44) | 1.80 [0.20, 58.90] (45) | 0.686* |
Active | 2.00 [0.10, 17.40] (47) | 1.80 [0.10, 16.40] (47) | |
IL-1β (pg/ml) | |||
Control | 0.24 [0.20, 0.66] (25) | 0.24 [0.20, 1.48] (23) | 0.309* |
Active | 0.24 [0.20, 0.68] (30) | 0.24 [0.20, 0.82] (25) | |
IL-6 (pg/ml) | |||
Control | 2.67 [0.23, 108.3] (26) | 2.59 [0.93, 6.63] (23) | 0.733* |
Active | 2.65 [0.26, 8.65] (31) | 3.20 [0.31, 10.62] (25) | |
IL-10 (pg/ml) | |||
Control | 0.91 [0.40, 2.63] (25) | 1.01 [0.31, 1.72] (23) | 0.799* |
Active | 1.06 [0.05, 2.88] (32) | 1.00 [0.11, 2.68] (27) | |
8-isoprostane (pg/ml) | |||
Control | 17.78 [4.55, 80.85] (25) | 22.12 [8.81, 38.40] (23) | 0.071* |
Active | 19.06 [6.01, 36.32] (30) | 17.66 [5.73, 35.66] (25) | |
MDA (μmol/L) | |||
Control | 1.23 (0.53) [45] | 1.45 (0.57) [45] | 0.786** |
Active | 1.22 (0.56) [47] | 1.48 (0.54) [47] |